Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs ...

Outcomes for patients with high-risk large B-cell lymphoma (LBCL), defined by an International Prognostic Index (IPI) score ...

The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the randomized phase 3 frontMIND ...

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

Combined-Modality Therapy for Clinical Stage I or II Hodgkin's Lymphoma: Long-Term Results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials Untreated ...

Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone ...

Selection bias is one of the most common issues in designing trials. This is illustrated in the PYRAMID trial, which showed a 2-year PFS of 78% for patients with non-GCB DLBCL compared with a 2-year ...

Chemotherapy drugs can shrink tumors or kill stray cancer cells left behind after surgery or radiation. It’s also a systemic treatment, meaning its purpose is to kill cancer cells throughout your body ...

Please provide your email address to receive an email when new articles are posted on . The addition of lenalidomide to R-CHOP chemotherapy improved survival outcomes among patients with newly ...